Am J Perinatol 2024; 41(02): 187-192
DOI: 10.1055/a-1673-5103
Original Article

Clinical Outcomes of a False-Positive Antenatal Diagnosis of Placenta Accreta Spectrum

Bahram Salmanian
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Amir A. Shamshirsaz
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Karin A. Fox
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Nazlisadat Meshinchi Asl
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Hadi Erfani
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Sarah E. Detlefs
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Michael Coburn
2   Department of Urology, Baylor College of Medicine, Houston, Texas
,
Jimmy Espinoza
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Ahmed Nassr
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Michael A. Belfort
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Steven L. Clark
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
,
Alireza A. Shamshirsaz
1   Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
› Author Affiliations

Abstract

Objective Antenatal diagnosis of placenta accreta spectrum (PAS) is critical to reduce maternal morbidity. While clinical outcomes of women with PAS have been extensively described, little information is available regarding the women who undergo cesarean delivery with a presumptive PAS diagnosis that is not confirmed by histopathologic examination. We sought to examine resource utilization and clinical outcomes of this group of women with a false-positive diagnosis of PAS.

Study Design This is a retrospective analysis of patients with prenatally diagnosed PAS cared for between 2015 and 2020 by our multidisciplinary PAS team. Maternal outcomes were examined. Univariate analysis was performed and a multivariate model was employed to compare outcomes between women with and without histopathologically confirmed PAS.

Results A total of 162 patients delivered with the preoperative diagnosis of PAS. Of these, 146 (90%) underwent hysterectomy and had histopathologic confirmation of PAS. Thirteen women did not undergo the planned hysterectomy. Three women underwent hysterectomy but pathologic examination did not confirm PAS. In comparing women with and without pathologic confirmation of PAS, the false-positive PAS group delivered later in pregnancy (34 vs. 33 weeks of gestation, p = 0.015) and had more planned surgery (88 vs. 47%, p = 0.002). There was no difference in skin incision type or hysterotomy placement for delivery. No significant difference in either the estimated blood loss or blood components transfused was noted between groups.

Conclusion Careful intraoperative evaluation of women with preoperatively presumed PAS resulted in a 3/149 (2%) retrospectively unnecessary hysterectomy. Management of women with PAS in experienced centers benefits patients in terms of both resource utilization and avoidance of unnecessary maternal morbidity, understanding that our results are produced in a center of excellence for PAS. We also propose a management protocol to assist in the avoidance of unnecessary hysterectomy in women with the preoperative diagnosis of PAS.

Key Points

  • Evaluation and delivery planning of patients with suspected placenta accreta spectrum in experienced centers provides acceptable outcomes.

  • Under specific circumstances, delivery of placenta may be attempted if placenta accreta is suspected.

  • Patients with suspected placenta accreta rarely undergo unindicated hysterectomy.



Publication History

Received: 11 June 2021

Accepted: 12 October 2021

Accepted Manuscript online:
19 October 2021

Article published online:
28 November 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Erfani H, Fox KA, Clark SL. et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. Am J Obstet Gynecol 2019; 221 (04) 337.e1-337.e5
  • 2 Shamshirsaz AA, Fox KA, Erfani H. et al. Outcomes of planned compared with urgent deliveries using a multidisciplinary team approach for morbidly adherent placenta. Obstet Gynecol 2018; 131 (02) 234-241
  • 3 Bowman ZS, Manuck TA, Eller AG, Simons M, Silver RM. Risk factors for unscheduled delivery in patients with placenta accreta. Am J Obstet Gynecol 2014; 210 (03) 241.e1-241.e6
  • 4 Berkley EM, Abuhamad AZ. Prenatal diagnosis of placenta accreta: is sonography all we need?. J Ultrasound Med 2013; 32 (08) 1345-1350
  • 5 Rac MW, Dashe JS, Wells CE, Moschos E, McIntire DD, Twickler DM. Ultrasound predictors of placental invasion: the Placenta Accreta Index. Am J Obstet Gynecol 2015; 212 (03) 343.e1-343.e7
  • 6 Rac MW, Moschos E, Wells CE, McIntire DD, Dashe JS, Twickler DM. Sonographic findings of morbidly adherent placenta in the first trimester. J Ultrasound Med 2016; 35 (02) 263-269
  • 7 Pagani G, Cali G, Acharya G. et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97 (01) 25-37
  • 8 Melcer Y, Jauniaux E, Maymon S. et al. Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa. Am J Obstet Gynecol 2018; 218 (04) 443.e1-443.e8
  • 9 Shamshirsaz AA, Fox KA, Salmanian B. et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol 2015; 212 (02) 218.e1-218.e9
  • 10 Marcellin L, Delorme P, Bonnet MP. et al. Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta. Am J Obstet Gynecol 2018; 219 (02) 193.e1-193.e9
  • 11 Abuhamad A. Morbidly adherent placenta. Semin Perinatol 2013; 37 (05) 359-364
  • 12 Silver RM, Barbour KD. Placenta accreta spectrum: accreta, increta, and percreta. Obstet Gynecol Clin North Am 2015; 42 (02) 381-402
  • 13 Coutinho CM, Giorgione V, Noel L. et al. Effectiveness of contingent screening for placenta accreta spectrum disorders based on persistent low-lying placenta and previous uterine surgery. Ultrasound Obstet Gynecol 2021; 57 (01) 91-96
  • 14 Shamshirsaz AA, Fox KA, Erfani H. et al. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol 2017; 216 (06) 612.e1-612.e5